Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant or stably-transformed bacterium encoding one or...
Reexamination Certificate
2006-03-13
2010-02-16
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant or stably-transformed bacterium encoding one or...
C424S185100, C424S192100, C424S234100, C424S277100, C435S252300, C536S023400, C536S023700
Reexamination Certificate
active
07662396
ABSTRACT:
The present invention provides recombinant polypeptides comprising an N-terminal fragment of an ActA protein or LLO protein fused to an antigen or a fragment thereof, nucleotides encoding same, recombinant vectors comprising same, and immunogenic and therapeutic methods utilizing same.
REFERENCES:
patent: 4521382 (1985-06-01), Kessick
patent: 4777239 (1988-10-01), Schoolnik et al.
patent: 4816253 (1989-03-01), Likhite et al.
patent: 5262177 (1993-11-01), Brown et al.
patent: 5342774 (1994-08-01), Boon et al.
patent: 5681570 (1997-10-01), Yang et al.
patent: 5824538 (1998-10-01), Branstrom et al.
patent: 5830702 (1998-11-01), Portnoy et al.
patent: 5858682 (1999-01-01), Gruenwald et al.
patent: 5877159 (1999-03-01), Powell et al.
patent: 6051237 (2000-04-01), Paterson
patent: 6479258 (2002-11-01), Short
patent: 6565852 (2003-05-01), Paterson
patent: 6767542 (2004-07-01), Paterson et al.
patent: 2003/0028206 (2003-02-01), Shiber
patent: 2003/0202985 (2003-10-01), Paterson
patent: 2004/0228877 (2004-11-01), Dubensky et al.
patent: 2005/0118184 (2005-06-01), Paterson et al.
patent: 2005/0129715 (2005-06-01), Paterson et al.
patent: 2006/0051380 (2006-03-01), Schulick et al.
patent: 2006/0093582 (2006-05-01), Paterson et al.
patent: 2006/0121053 (2006-06-01), Sweeney et al.
patent: 2006/0205067 (2006-09-01), Paterson et al.
patent: 0 902 086 (1999-03-01), None
patent: WO 93/15212 (1993-08-01), None
patent: WO 94/17192 (1994-08-01), None
patent: WO 96/14087 (1996-05-01), None
patent: WO 96/34531 (1996-11-01), None
patent: WO 98/48026 (1998-10-01), None
patent: WO 99/06544 (1999-02-01), None
patent: WO 99/07861 (1999-02-01), None
patent: WO 99/10496 (1999-03-01), None
patent: WO 01/27295 (2001-04-01), None
patent: WO 01/72329 (2001-10-01), None
patent: WO 03/092600 (2003-11-01), None
patent: WO 2004/006837 (2004-01-01), None
Lebrun et al, Molecular Microbiology 21(3): 579-592, 1996.
Paglia et al, Eur J Immunol 27: 1570-1575, 1997.
Guzman et al, Eur J Immunol 28: 1807-1814, 1998.
Bourquin et al, Eur J Immunol 30: 3663-3671, 2000.
Witkowski et al, Biochemistry 38(36): 11643-50, Sep. 7, 1999.
Seffernick et al, J Bacteriol 183 (8): 2405-10, Apr. 2001.
Golsteyn et al, J Cell Sci 110: 1893-1906, 1997.
Adams at al. (1992) “Cre-loxrecombination inEscherichia colicells. Mechanistic differences from the in vitro reaction.”J. Mol. Biol.226:661-673.
Allison et al. (1997) “Cloning and characterization of a Prevotella melaninogenica hemolysin,”Infect Immun.65(7):2765-71.
An et al. (1996) “A recombinant minigene vaccine containing a nonameric cytoxic-T-Lymphocyte epitope confers limited protection againstListeria monocytogenesinfection”Infect. Immun64,(5):1685-1693.
Anderson (1998) “Human gene therapy,”Nature.Apr. 30:392(6679 Suppl):25-30.
Angelakopoulos et al. (2002) “Safety and shedding of an attenuated strain ofListeria monocytogeneswith a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation,”Infect Immun.70(7):3592-601.
Attwood et al. (2000) “The Babel of Bioinformatics”Science290(5491):471-473.
Awwad (1989) “Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.”Cancer Res.49(7): 1649-1654.
Barry et al. (1992) “Pathogenicity and immunogenicity ofListeria monocytogenessmall-plaque mutants defective for intracellular growth and cell-to-cell spread.”Infection and Immunity60 (4):1625-32.
Bast et al. (1975) “Antitumor activity of bacterial infection. II. effect ofListeria monocytogeneson growth of a guinea pig hepatoma.”J Natl. Cancer Inst., 54(3): 757-761.
Bear (1986) “Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.”Cancer Res.Apr:46(4 Pt 1):1805-12.
Beatly, Dissertation Abstracts International, 2000, 61/10B:6224 Abstract Only.
Bernhard et al. (2002) “Vaccination against the HER-2
eu oncogenic protein.”Endocrine-Related Cancer, 9:33-44.
Bielecki et al. (1990) “Bacillus subtilis expressing a haemolysin gene fromListeria monocytogenescan grow in mammalian cells”Nature354:175-176.
Billington et al. (1997) “The Arcanobacterium (Actinomyces) pyogenes hemolysin, pyolysin, is a novel member of the thiol-activated cytolysin family,”J Bacteriol.Oct.;179(19):6100-6.
Boomer at al. (1988) “Enhanced recognition of a modified peptide antigen by cytotoxic T cells specific for influenza nucleoprotein,” Cell 52: 253-258.
Boon et al. (2006) “Human T cell responses against melanoma”Annu Rev Immunol.24:175-208.
Bourquin et al. (2000) “Myelin oligodendrocyte glycoprotein-DNA vaccination induces antibody-mediated autoaggression in experimental autoimmune encephalomyelitis”Eur J Immunol30:3663-3671.
Boyer et al. (2005) “DNA primeListeriaboost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication.”Virology.Mar. 1;333(1):88-101.
Brasseur et al. (1992) “Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors.”Int J Cancer52(5):839-841.
Brockstedt et al. (2004) “Listeria-based cancer vaccines that segregate immunogenictty from toxicity.”Proc Natl Aced Sci USA. 101(38):13832-7.
Bron et al. (2004) “Identification ofLactobacillus plantarumgenes that are induced in the gastrointestinal tract of mice.”J Bacterial.Sep.;186(17):5721-9.
Brown et al. (1988) “Site-specific integration inSaccharopolyspora erythraeaand multisite integration in Streptomyces lividans of actinomycete plasmid pSE101.”J. Bacteriology170: 2287-2295.
Bruhn et al. (2005) “Characterization of anti-self CD8 T-cell responses stimulated by recombinantListeria monocytogenesexpressing the melanoma antigen TRP-2.”Vaccine.Jul. 21;23(33):4263-72.
Brundage et al. (1993) “Expression and phosphorylation of theListeria monocytogenesActA protein in mammalian cells.”Proc. Natl. Acad. Sci. USA90: 11890-11894.
Bubert et al. (1997) “TheListeria monocytogenesiap gene as an indicator gene for the study of PrfA-dependent regulation.”Mol Gen Genet.Sep.;256(1):54-62.
Burnham (2003) “Bad bugs: good for cancer therapy?”Drug Discovery Today8(2):54-55.
Calendar et al. Poster presented at the ISOPOL Meeting 2001, http://64.233.169.104/search?q=cache:mA—uJpQsCrcJ:www.ma.uni-heidelberg.de/inst/imh/download/isopol.doc+Portnoy+Isopol+2001&hl=en&ct=cink&cd=3&gl=us.
Camilli et al. (1993) “Dual roles of plcA inListeria monocytogenespathogenesis.”Mol. Microbiol.8:143-157.
Carbone (1989) “Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization.”J Exp Med169:603-612.
Carbone (1990) “Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo.”J Exp Med171:377-387.
Chamberlain et al. (2000) “Innovations and strategies for the development of anticancer vaccines.”Expert Opinion on Pharmacatherapy1(4):603-614.
Courvalin et al. (1995) “Gene transfer from bacteria to mammalian cells,”C R Acad Sci III.Dec;318(12):1207-12.
Cunto-Amesty et al. (2003) “Strategies in cancer vaccines development.”Int J Parasitol.33(5-6):597-613.
Dakappagari et al. (2000) “Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.”Cancer Res.Jul. 15;60(14):3782-9.
Darji et al. (2003) “Induction of immune responses by attenuated isogenic mutant strains ofListeria rnonocytogenes.” Vaccine1;21 Suppl 2:S102-9.
Darji et al. (1997) “Oral somatic transgene vaccination using attenuatedS. typhimurium” Cell91:765-775.
Darji et al. (1995) “Hyperexpression of listeriolysin in the nonp
Pan Zhen-kun
Paterson Yvonne
Sewell Duane
Singh Reshma
Souders Nicholas
Cohen Mark S.
Huynh Phuong
Pearl Cohen Zedek Latzer LLP
The Trustees of the University of Pennsylvania
LandOfFree
Compositions and methods for enhancing the immunogenicity of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for enhancing the immunogenicity of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for enhancing the immunogenicity of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4184671